Unique administration of drugs with large patient benefits

Karessa is a Swedish pharmaceutical company that aims to revolutionise the market for medicinal products through innovation and a patented drug delivery platform..

Our medicinal products will not be taken in tablet form, but will instead be delivered directly into the bloodstream via a film that is applied discreetly to the oral mucosa. The main advantages for the patient include a faster and more reliable effect compared with today's preparations.

Our business model is based on combining proven, effective and approved substances with our own patented drug delivery platform. Through this combination, we are  generating significant benefits, both for the patient and for Karessa itself. For Karessa as a company, the combination means a shorter time to market, lower development costs and reduced risk compared with traditional drug development.

Latest presentation

Stefan Arver förklarar erektil dysfunktion
Watch clip (SWE)

The plattform


Plattform presentation

The film distribution

The film distribution into the blood stream
Watch clip

 

Press releases

  • 3/12/2019

    Midazolam – first step taken

    Karessa has now completed the first step in the development of Midazolam, Karessa.

  • 12/28/2018

    Karessa – new research and development area

    Karessa Pharma Holding AB (Publ) has received an exclusive license from Uppsalagruppen Medical AB for development of preparations within the benzodiazepine group based on the patented transbuccal drug delivery platform. The objective is with limited contributions develop a prioritized product including preclinical phase, thereafter, finalizing agreements with partners for further development. This means the company will expand to further development area except erectile dysfunction.

undefined






LATEST NEWS

Karessa participates in BIO-Europe Spring

Karessa will participate in the congress, which includes a large number of biotech companies that gather for individual meetings on opportunities for future collaborations. We will be able to present Karessa and its unique drug delivery technology and research. A large number of companies participate, including large international pharma groups, which provide opportunities for presentations and discussions about future partnerships around our products. The meeting takes place on March 25-27, 2019, and comprises over 1,500 companies and has more than 14,500 participants.

Exciting development of the patented drug delivery platform

Karessa is developing pharmaceuticals based on the unique patented alginate drug delivery technique, where the pharmaceutical is placed in the buccal cavity for direct absorption into the bloodstream. This is also used by the Swedish research company Klaria, which on January 22, 2019, signed an agreement with Purdue Pharma regarding development of Adrenalin for the treatment of acute allergic conditions. The agreement is worth close to 500 million SEK and is the second product in the cooperation. We are seeing an increasing interest in our technology with a quick, direct and effective delivery of the pharmaceutical from the buccal cavity into the bloodstream.

Karessa at NLS days

NLS days were held on September 10-12, 2018, in Stockholm. The meeting gathered about 800 companies and organizations in life science, with 1,200 participants. Karessa participated, among other things with a presentation of the company's business concept and projects within erectile dysfunction facing potential stakeholders and partners.

High frequency of sexual problems associated with prostate cancer

In a new published Scandinavian study on treated prostate cancer patients, patients who were sexually active received major problems with sex life afterwards. Erectile dysfunction and accompanying problems were measured at 72–92% among patients from Scandinavia, and were several times more common than untreated patients. The study highlights the importance of clinical need to care for these patients and help them to improve sexual health and quality of life. 

Karessa's work is mentioned

New article about Karessa's unique platform and development work with drugs to treat erectile dysfunction.

Read the article (in Swedish) ”Utvecklar läkemedel mot impotens” 
(December 2017)

undefined40 per cent of all 40-year-old men are affected

40 per cent of all 40-year-old men suffer from erectile dysfunction, i.e. the inability to achieve and maintain an erection sufficient to enable successful intercourse. The reasons may be physical, mental, or a combination of both. The biggest underlying factors include age, other medications and lifestyle.

Read more about the market for medicinal products treating erectile dysfunction here.

undefined

Calendar